Related Experiment Videos
Blockade of selectin-mediated leukocyte adhesion improves postischemic function in lamb hearts
T Miura1, D P Nelson, M L Schermerhorn
1Department of Cardiovascular Surgery, Children's Hospital, Boston, Massachusetts 02115, USA.
The Annals of Thoracic Surgery
|November 1, 1996
Summary
Fucoidin, a selectin blocker, improved heart function and blood flow after cold ischemia in lambs. This suggests blocking leukocyte-endothelial interactions may protect against ischemia/reperfusion injury.
Area of Science:
- Cardiovascular Research
- Ischemia/Reperfusion Injury
- Molecular Biology
Background:
- Leukocyte-endothelial interactions are critical in ischemia/reperfusion (I/R) injury.
- Selectins (L-, P-, E-selectin) mediate leukocyte rolling on endothelium via specific ligand binding.
- Fucoidin, a seaweed-derived oligosaccharide, inhibits selectin activity.
Purpose of the Study:
- To investigate the therapeutic potential of fucoidin in mitigating I/R injury.
- To evaluate the effect of selectin blockade on neonatal lamb heart function post-ischemia.
Main Methods:
- A blood-perfused neonatal lamb heart model was subjected to 2 hours of cold cardioplegic ischemia.
- Fucoidin (30 mg/L) was administered at reperfusion in the experimental group (Group F, n=8).
- Left ventricular function, coronary blood flow, myocardial oxygen consumption, and white blood cell counts were measured.
Main Results:
- Fucoidin treatment significantly improved recovery of left ventricular developed pressure and its first derivatives compared to controls (Group C, n=9).
- Post-ischemic coronary blood flow and myocardial oxygen consumption were significantly higher in the fucoidin group.
- While white blood cell counts were higher post-reperfusion in the fucoidin group, functional recovery was enhanced.
Conclusions:
- Selectin blockade with fucoidin demonstrates a protective effect against cold ischemia-induced cardiac dysfunction.
- These findings support the role of leukocyte-endothelial interactions in I/R injury.
- Selectin inhibition represents a promising therapeutic strategy for managing cardiac I/R injury.